U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiova

Date postedMarch 22, 2024
Industry,

ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients. In addition, the enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins. They also include new indications for primary hyperlipidemia, alone or in combination with a statin, and are the only LDL-C lowering non-statin drugs indicated for primary prevention patients. Read more...

Categories

Community Women in PC Industry Patient Care and Advocacy

Most Recent Posts

Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight Date postedDecember 20, 2024Posted TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with FCS Date postedDecember 19, 2024Posted Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial Date postedDecember 4, 2024Posted AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE Date postedNovember 26, 2024Posted Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA Date postedNovember 22, 2024Posted